Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK0633 in atherosclerosis
NCT00421278Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Nov 2006
- Primary completion
- Dec 2006
- Modality
- Small Molecules
01
Overview
Phase 2, single-arm trial of setileuton in atherosclerosis, sponsored by Merck & Co. Primary endpoint: High-sensitivity C-reactive protein at 4 weeks. Started Nov 2006; status: completed.
02
Drugs
setileuton
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on NCT00421278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00421278.